Standards & Regulation

A regulatory science push in the UK includes centres for digital transformation, AI and more.

Robert F Kennedy Jr’s recent speech suggests that investigations into childhood vaccines and over-medication could be on the cards.

The Access to Medicine Foundation has developed the 2026 AMR Benchmark to recognize and promote urgency in the ongoing AMR challenge.

Within two years, pharma companies may be able to rely on technology to automatically create and cross-check entire regulatory submissions.

Stakeholders explain why the NIH’s move to cap indirect costs associated with research grants could damage medical innovation.

US-based pharmaceutical associations fear the supply chain repercussions of tariffs, and offer advice for a more sustainable alternative.

We speak with Sanofi’s Anju Bhalla about its appeal against NICE’s final draft guidance for Sarclisa.

Senate committee votes in favor of the nomination; full Senate vote will be next.

The Trump administration’s move to pause federal funding while projects are vetted causes concern and lawsuits

What can we expect the US life sciences sector to look like over the course of the next four years as Donald Trump takes up his presidency?